On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Patient-controlled epidural analgesia after TKA was associated with reduced postoperative pain but had no effect on postoperative nausea and vomiting incidence.